Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
复制标题

DOI:
10.1038/onc.2013.444
复制
发表时间:
2014-10-16
期刊:
影响因子:
8
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

尽管他莫昔芬在临床上取得了成功,但其耐药性仍然是乳腺癌的主要挑战。在这里,我们表明Aurora-A通过调节雌激素受体(ER)α来决定他莫昔芬的敏感性。Aurora-A的异位表达减少,Aurora-A的缺失增强ERα阳性乳腺癌对他莫昔芬的敏感性。Aurora-A升高与ERα阳性肿瘤的复发显著相关。值得注意的是,Aurora-A抑制剂MLN 8237目前正在临床试验中,与他莫昔芬协同作用,克服了他莫昔芬耐药性。此外,Aurora-A与丝氨酸-167和-305上的ERα相互作用并使其磷酸化,导致ERα DNA结合和转录活性增加。Aurora-A水平升高与ERα阳性而非阴性乳腺癌的无病生存率显著相关。这些数据表明Aurora-A在他莫昔芬耐药中起关键作用,ERα是Aurora-A的真正底物。因此,Aurora-A代表ERα阳性肿瘤的预后标志物和他莫昔芬耐药乳腺癌的关键治疗靶点,Aurora-A抑制剂可用作他莫昔芬耐药肿瘤的独立或联合药物。
Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of estrogen receptor (ER)α. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERα-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ERα-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen-resistance. Furthermore, Aurora-A interacts with and phosphorylates ERα on serine-167 and -305, leading to increase in ERα DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ERα-positive but not -negative breast cancers. These data suggest that Aurora-A plays a pivotal role in tamoxifen resistance and ERα is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ERα-positive tumor and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.
DOI: 10.1038/onc.2012.628
发表时间: 2014-01-30
期刊: Oncogene
影响因子: 8
作者:
通讯作者: --
DOI: 10.2165/00129785-200404010-00003
发表时间: 2004-01-01
期刊: American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
影响因子: --
作者:
Barkhem, Tomas;Nilsson, Stefan;Gustafsson, Jan-Ake
通讯作者: Gustafsson, Jan-Ake
DOI: 10.4161/cc.21194
发表时间: 2012-09-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Holz, Marina K.
通讯作者: Holz, Marina K.
DOI: 10.1074/jbc.m406802200
发表时间: 2004-12-10
影响因子: 4.8
作者:
Li, QY;Kaneko, S;Cheng, JQ
通讯作者: Cheng, JQ
DOI: 10.1128/mcb.00916-08
发表时间: 2010-01-15
影响因子: 5.3
作者:
Lim, Kian-Huat;Brady, Donita C.;Counter, Christopher M.
通讯作者: Counter, Christopher M.